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Abstract 
We reported that the combination of ROS scavengers MnTBAP, 
catalase, and glutathione (MCG) given before 2 h cold cardiac ischemia better 
protected cardiac mitochondria against cold ischemia-induced damage and 
warm reperfusion (IR) than did MnTBAP alone. Here we hypothesized that 
high K+ cardioplegia (CP) plus MCG would improve mitochondrial 
bioenergetics and provide added cardiac functional protection against IR 
injury. We used fluorescence spectrophotometry to monitor redox balance 
(NADH/FAD), O2•−, and mitochondrial Ca2+ (m[Ca2+]) in the left ventricular 
wall. Guinea pig isolated hearts were perfused with either Krebs Ringer’s (KR) 
solution (control), CP, or CP+MCG, before and during 27°C perfusion followed 
immediately by 2 h of global ischemia at 27°C. Drugs were washed out with 
KR at the onset of 2 h 37°C reperfusion. After 120 min reperfusion myocardial 
infarction was lowest in the CP+MCG group and highest in the KR group. 
Developed left ventricular pressure recovery was similar in CP and CP+MCG 
groups and was better than in the KR group. O2•−, m[Ca2+ ], NADH/FAD were 
significantly different between the treatment and KR groups. O2•− was lower 
in the CP+MCG group than in the CP group. This study suggests that CP and 
ROS scavengers act in parallel to improve mitochondrial bioenergetics and to 
provide functional protection against IR injury at 27°C. 
Keywords: ROS scavengers, mitochondrial redox state, hypothermia, 
ischemia 
Introduction 
Hypothermia is commonly used to protect hearts against 
subsequent ischemia and reperfusion (IR) injury. The lower the 
temperature, the more protective is hypothermia against cardiac IR 
injury so ischemic time can be prolonged. Hypothermia, however, is a 
two-edged sword because of the intrinsic deleterious effects that 
become increasingly greater the lower the temperature. For example, 
hypothermia causes mitochondrial (m) Ca2+ loading1 secondary to 
reduced Na+/K+ ATPase activity and cytosolic Na+ and Ca2+ loading, 
and is coupled to slowed mitochondrial enzyme function as evidenced 
by increased NADH.1, 2 These factors lead to impaired mitochondrial 
electron transport chain (ETC) activity which may allow electron leak 
and augments superoxide (O2•−) generation as well as other reactive 
oxygen species (ROS). With inefficient scavenging of ROS by 
temperature sensitive scavengers such as superoxide dismutase (SOD) 
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and catalase, this could further enhance ROS emission (generation – 
scavenging) during cold perfusion. 
ROS generation and mCa2+ loading during hypothermia may 
together reduce the potentially optimal protective effect of 
hypothermia due to ROS-induced cell injury. Many cold cardioplegic 
solutions (CP) contain ROS scavengers,3-6 and it is thought these ROS 
scavengers are useful because they generally scavenge the “bad” ROS 
on warm reperfusion after cold storage. However, ROS is also 
generated during ischemia.7, 8 Moreover, we reported that hypothermic 
perfusion, per se, without concomitant ischemia also results in ROS 
emission that is inversely proportional to temperatures below 37°C 
largely because of reduced ROS scavenging capability.9 
In a previous study2 we examined the scavenging of O2•− and 
other oxidants produced during cold perfusion with normal K+ Krebs 
Ringer’s solution before cold ischemia. We used a cocktail of 
scavengers, i.e. Mn(III) tetrakis (4-benzoic acid) porphyrin (MnTBAP), 
a mitochondrial SOD2 mimetic, catalase, an enzyme that catalyzes 
H2O2 to H2O, and glutathione, a tripeptide that in its reduced form 
scavenges ROS, and found that the combination (MCG) provided 
better mitochondrial preservation as shown by a more normalized 
redox state, less mCa2+ accumulation, and less ROS emission 
compared to control hearts after 2 h cold ischemia. This preservation 
of the mitochondrial bioenergetic state was associated with improved 
cardiac function and reduced infarct size. Interestingly, we also 
observed that scavenging O2•− with MnTBAP alone resulted in a more 
oxidized mitochondrial redox state as evidenced by lower NADH and 
higher FAD, greater mCa2+ loading, more ROS emission, and worse 
cardiac function compared to the control and the combination of 
MnTBAP, catalase and glutathione (MCG).2 The implication of the prior 
study was that O2•− and its downstream products are present in higher 
concentrations during cold perfusion and so are important factors to be 
scavenged during cold storage. 
Although our prior study2 showed an additive effect of ROS 
scavengers when added to hypothermic normal K+ perfusion in 
improving cardiac recovery after IR, in the clinical setting of coronary 
artery bypass surgery hypothermia is applied during perfusion with a 
CP solution. CP plus hypothermia may better protect against IR injury 
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than hypothermia or CP alone.3, 5, 6 Thus our aim was to determine if 
perfusion with a cold CP solution enhances cardiac recovery after IR 
more than hypothermia alone, and if adding the cocktail of ROS 
scavengers (MCG) used in our previous study has an additive effect 
with cold CP solution in protecting the heart against IR injury. Because 
mitochondrial function and ROS emission are integral factors in IR 
injury, we also investigated if there is an additive effect of ROS 
scavengers with cold CP solution on improving mitochondrial function 
as assessed continuously on line by measuring mitochondrial redox 
state (NADH, FAD), ROS, and [Ca2+]. 
Materials and Methods 
Langendorff heart preparation 
The investigation conformed to the Guide for the Care and Use 
of Laboratory Animals published by the NIH (Publication No. 85-23, 
1996) and was approved by the institutional animal care committee. 
Our methods have been described previously in detail.9-14 Guinea pigs 
(n=73) were anesthetized with ketamine (50 mg/kg, IP), and heparin 
(5000 U, IP) was administered to prevent clotting. Following 
decapitation and thoracotomy, hearts were removed and perfused at 
55 mmHg via the aortic root with a Krebs-Ringer’s (KR) solution 
containing (mM): 138 Na+, 4.5 K+, 1.2 Mg2+, 2.5 Ca2+, 134 Cl−, 14.5 
HCO3−, 1.2 H2PO4−, 11.5 glucose, 2 pyruvate, 16 mannitol, 0.1 
probenecid, 0.05 EDTA, and 5 U/l insulin gassed with ~97% O2 and 
~3% CO2 (pH 7.4±0.01) at 37°C. Left ventricular pressure (LVP) was 
measured with a saline-filled latex balloon inserted into the left 
ventricle. Spontaneous heart rate was monitored with bipolar 
electrodes placed in the right atrial and ventricular walls. Coronary 
flow was measured by an ultrasonic flowmeter (Transonic T106X, 
Ithaca, NY) placed directly into the aortic inflow line. Cardiac O2 
consumption (MVO2) was calculated as coronary flow • heart weight−1 
• (PaO2 – PvO2) • 24 μl O2 / ml (37°C) at 760 mmHg, and cardiac 
efficiency as developed LVP • heart rate / MVO2, and %O2 extraction 
as 100 • (PaO2 – PvO2) / PaO2 (where PaO2 and PvO2 are arterial and 
venous PO2, respectively). 
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Online assessment of mitochondrial bioenergetic 
function 
All fluorescence signals were detected in photons/second. All 
FAD and most NADH are confined to mitochondria.15-17 Most of the O2•− 
during cardiac IR injury likely originates from mitochondria while only 
a small amount is derived from non-mitochondrial sources.9 Non-
myocyte sources such as endothelial and vascular cells also contribute 
to the total O2•− generated. However, the overall contribution of this 
source of ROS is minimal considering that mitochondrial content of 
endothelial cells ranges between 2-5%18 while mitochondria constitute 
22-37% of myocyte volume.19, 20 These observations indicate that 
most of the O2•− generated in hearts subject to IR injury originates in 
cardiac myocyte mitochondria. 
NADH and FAD, m[Ca2+], and O2•− emission were measured 
continuously at the left ventricle (LV) free wall using one of four 
excitation and emission fluorescence spectra9-14 in different subsets of 
hearts. A trifurcated fiberoptic probe was placed against the LV to 
excite and record light signals at specific wavelengths using 
spectrophotofluorometers (SLM Instruments Inc, Urbana, IL; or PTI, 
London, Ontario). 
In a subset of hearts, as described previously,11, 12, 21 10 μM 
dihydroethidium (DHE, Molecular Probes, Eugene, OR), a fluorescent 
probe used to detect the O2•− radical,8, 22, 23 was loaded for 20 min and 
washed out; the LV free wall was excited at 540 nm, and light 
emission was recorded at 590 nm. O2•− non-enzymatically converts 
DHE to 2-hydroxyethidium (2-OH-E+) or a labile precursor that 
appears to be rapidly made and fluoresces at a slightly shorter 
wavelength than the heme-peroxidase oxidation product ethidium that 
can intercalate with DNA.22, 23 In other hearts NADH and FAD 
autofluorescence was assessed at 350 nm excitation and 450 and 390 
nm emissions, and at 480 nm excitation and 540 nm emission, 
respectively.1, 7, 13, 17 
Alternatively, other hearts were loaded with 6 μM indo 1 AM 
(Molecular Probes, Eugene, OR) for 30 min to measure Ca2+ transients 
at an excitation of 350 nm and emissions were recorded at 390 and 
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450 nm. After initially observing cytosolic Ca2+ transients, hearts were 
perfused for 15 min with 100 μM MnCl2 to quench the cytosolic indo 1 
signal;24, 25 this was followed by a 15 min washout. To estimate actual 
m[Ca2+], NADH autofluorescence was subtracted from the underlying 
changes in mCa2+ fluorescent signals for each group.2, 7, 26 pH in the 
range of 6.2-8.0 does not alter the Ca2+ fluorescence signal in our 
model.11 This excludes the possibility of lactic acidosis during ischemia 
from having a significant effect on fluorescence signals. 
Protocol 
Hearts were randomly divided into three experimental groups: 
control (CON; KR 4 mM K+), high K+ cardioplegia (CP; KR with 16 mM 
K+), and CP plus a combination of ROS scavengers consists of 10 μM 
MnTBAP (A.G. Scientific Inc, San Diego, CA), 50 U/ml catalase (Sigma-
Aldrich, St. Louis, MO), and 500 μM glutathione (Sigma-Aldrich, St. 
Louis, MO) (CP+MCG). Each heart initially underwent a stabilization 
period to attain a steady rhythm and level of contractility; this was 
followed by loading and washout of unbound dye to measure either 
m[Ca2+] or O2•−. NADH and FAD autofluorescence were assessed 
simultaneously. All hearts undergoing ischemia were perfused with 
either KR alone (CON), CP, or CP+MCG, first for 10 min at 37°C, and 
then continued during an additional 30 min at 27°C. This was followed 
by 120 min of global 27°C ischemia and 120 min reperfusion at 37°C. 
At the end of each experiment the ventricles were cut into 4-5 
transverse sections of approximately 3 mm and incubated in buffered 
0.1% 2,3,5-triphenyltetrazolium chloride to distinguish viable tissue 
(stained) from necrotic tissue (unstained) for estimating infarct size.27 
Statistical analysis 
All data are expressed as means ± SEM. Among-group data 
were compared by ANOVA to determine significance (Super ANOVA 
1.11 software; Abacus Concepts, Berkeley, CA) at specific times. If F 
values were significant (P < 0.05), post hoc comparisons of means 
tests (Student-Newman-Keuls) were used to compare the groups 
within each subset. Differences among means were considered 
statistically significant when P < 0.05 (two tailed). 
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Results 
Baseline values were not different among treatment groups. 
Similar to our previous study,28 values for all measurements did not 
change throughout the duration of the time control experiments (data 
not shown), which indicates stability of the preparation. Figures 1A 
and 1B show timeline changes in systolic minus diastolic LVP 
(developed LVP) and diastolic LVP (diaLVP), respectively. All treated 
hearts were arrested (due to the high [K+] in CP) during the 10 min 
perfusion at 37°C and the 30 min perfusion at 27°C before ischemia. 
By the end of 60 min reperfusion developed LVP was higher in CP and 
CP+MCG groups than in the CON group, and diaLVP was lower in the 
CP and CP+MCG groups compared to the CON group. Values at 120 
min reperfusion were similar to those at 60 min. Cardiac contraction, 
relaxation, and metabolic data were compared for all groups at 60 min 
reperfusion (Table 1). On reperfusion, each index was more improved 
in the treatment groups compared to the CON group. Although some 
indices in Table 1 are different between CP+MCG and CP alone, these 
were not statistically significant. 
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Figure 1 
Time course of changes in developed LVP (A) and diastolic LVP (B) at baseline, during 
treatment, hypothermia, cold ischemia, and warm reperfusion for control (n=15), CP 
(n=16), and CP+MCG (n=14) groups. The arrow indicates where the data point was 
recorded during treatment at 37°C. The solid horizontal bar indicates the period of 
treatment at 27°C. The period between the two unbroken vertical lines refers to 
ischemia. *P < 0.05 values vs. baseline within each group; #P < 0.05 each treatment 
vs. the control group; ¶P < 0.05, CP+MCG vs. CP alone. 
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 Baseline Reperfusion 60 min 
Heart Rate (beats/min) 
 Control 276±9 269±6 
 CP 269±6 262±7 
 CP+MCG 269±15 279±8 
dP/dt max (mmHg/s) 
 Control 2024±175 735±142 
 CP 1909±193 1221±141# 
 CP+MCG 2012±168 1040±67# 
dP/dt min (mmHg/s) 
 Control −1502±124 −516±101 
 CP −1542±206 −904±112# 
 CP+MCG −1577±171 −716±54# 
O2 consumption (μl O2/g/min) 
 Control 105.1±7.8 57.6±6.8 
 CP 102.2±7.0 81.4±6.8# 
 CP+MCG 121.8±8.7 87.3±5.6# 
% O2 extraction 
 Control 72±4 76±5 
 CP 76±2 85±2# 
 CP+MCG 73±3 81±4 
Cardiac efficiency (mmHg • beat • 0.1 μL O2 / g) 
 Control 23±3 14±2 
 CP 23±1 16±1 
 CP+MCG 18±1 14±2 
 
Table 1 Changes in heart rate, maximal rates of contractility (dP/dt max) and 
relaxation (dP/dt min), O2 consumption, % O2 extraction, and cardiac efficiency at 
baseline and 60 min reperfusion. 
Values are mean ± SEM 
Abbreviations: CP, high K+ cardioplegia; CP+MCG, high K+ cardioplegia with MnTBAP, 
catalase, and glutathione. 
#P < 0.05 each treatment vs. the control group 
¶P < 0.05, CP+MCG vs. CP 
Figures 2A and 2B, respectively, show timeline changes in NADH 
and FAD. An increase in NADH and a decrease in FAD indicate a more 
reduced mitochondrial redox state.7, 26 NADH increased during 
treatment with CP and CP+MCG before hypothermia and this was 
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followed by an additional increase during the first 5 min of ischemia. 
Conversely, FAD decreased during treatment with CP and more so 
during ischemia with CP+MCG. On reperfusion, mitochondrial NADH 
and FAD were more preserved in the CP and CP+MCG groups than in 
the CON group. 
 
Figure 2 Time course of changes in NADH autofluorescence (A) and FAD 
autofluorescence (B) at baseline, during treatment, hypothermia, cold ischemia, and 
warm reperfusion in control (n=5), CP (n=5), and CP+MCG (n=5) groups. The arrow 
indicates where the data point was recorded during treatment at 37°C. The solid 
horizontal bar indicates the period of treatment at 27°C. The period between the two 
unbroken vertical lines refers to ischemia. *P < 0.05 values vs. baseline within each 
group; #P < 0.05 each treatment vs. the control group; ¶P < 0.05, CP+MCG vs. CP 
alone. 
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Figure 3A shows timeline changes in O2•− emission in the CON 
and treatment groups. CP perfusion alone caused a decrease in O2•− 
emission and cold perfusion increased the O2•− emission slightly in the 
CON group. During initial ischemia, O2•− emission increased in all 
groups and surged during the last 20 min of ischemia to reach a 
significantly higher value in the CON group compared to the treatment 
groups, with CP+MCG having the lowest O2•− emission throughout 
ischemia. On reperfusion, the O2•− signal declined in all groups and by 
the end of reperfusion, O2•− emission was more elevated in the CON 
group than in the CP or CP+MCG groups. Figure 3B shows m[Ca2+] at 
baseline and at 60 min reperfusion. m[Ca2+] was not different among 
groups during ischemia (data not shown). At 60 min reperfusion, CP 
and CP+MCG treatments resulted in less mCa2+ loading compared to 
CON with no significant difference between CP and CP+MCG groups by 
the end of reperfusion. 
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Figure 3 (A). Time course of changes in superoxide (O2•−) signal at baseline, during 
treatment, hypothermia, cold ischemia, and warm reperfusion in control (n=4), CP 
(n=4), and CP+MCG (n=4) groups. The arrow indicates where the data point was 
recorded during treatment at 37°C. The solid horizontal bar indicates the period of 
treatment at 27°C. The period between the two unbroken vertical lines refers to 
ischemia. Figure 3(B). Mitochondrial Ca2+ levels in control (n=6), CP (n=7), and 
CP+MCG (n=5) groups at baseline and 60 min of reperfusion. *P < 0.05 values vs. 
baseline within each group; #P < 0.05 each treatment vs. the control group; ¶P < 
0.05, CP+MCG vs. CP alone. 
Figure 4 shows that CP and CP+MCG groups had smaller infarct 
sizes compared to the CON group; CP+MCG group showed the 
smallest infarct sizes. Table 2 shows cardiac functional recovery and 
changes in mitochondrial bioenergetics for two additional treatment 
groups: CP+MnTBAP and CP+catalase+glutathione. There were no 
significant differences in cardiac function and infarct size among these 
groups when compared to CP alone. 
 
Figure 4 Infarct size as a percentage of total ventricular weight measured after 120 
min reperfusion from random hearts in control (n=10), CP (n=8), and CP+MCG (n=6). 
#P < 0.05 each treatment vs. the control group; ¶P < 0.05, CP+MCG vs. CP alone. 
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 Baseline Reperfusion 60 minutes 
Developed left ventricular pressure (mmHg) 
 CP+M (n=14) 86±3 43±5# 
 CP+CG (n=14) 90±1 42±3# 
Diastolic left ventricular pressure (mmHg) 
 CP+M (n=14) 0.6±0.4 12.4±3#¶ 
 CP+CG (n=14) 0.4±0.2 10.3±4.2#¶ 
NADH (afu) 
 CP+M (n=5) 59.7±0.1 44.9±1.6¶ 
 CP+CG (n=5) 60.1±0.3 47.6±2.1¶ 
FAD (afu) 
 CP+M (n=5) 12.9±0.1 13.8±0.6 
 CP+CG (n=5) 13.1±0.1 14.8±0.3 
Superoxide (afu) 
 CP+M (n=5) 2.12±0.01 1.76±0.09# 
 CP+CG (n=6) 2.1±0.02 1.89±0.13# 
Mitochondrial Ca2+ (nM) 
 CP+M (n=4) 184±19 207±53# 
 CP+CG (n=3) 155±1 186±47# 
Infarct Size % 
 CP+M (n=6) - 39±4# 
 CP+CG (n=6) - 31±5# 
 
Table 2 Changes in developed left ventricular pressure, diastolic left ventricular 
pressure, and mitochondrial bioenergetics (NADH, FAD, superoxide, mitochondrial 
Ca2+) at baseline and 60 min reperfusion in two additional treatment groups: CP+M, 
CP+CG 
Values are mean ± SEM 
Abbreviations: CP+M, high K+ cardioplegia with MnTbap; CP+CG, high K+ cardioplegia 
with catalase+glutathione 
#P < 0.05 each treatment vs. the control group 
¶P < 0.05, CP+M or CP+CG vs. CP 
Discussion 
The major findings of this study are that exposure to 
hypothermic (27°C) CP before and during ischemia protects hearts, 
preserves mitochondrial redox state (NADH/FAD), lowers m[Ca2+] 
during reperfusion, and reduces O2•− emission during IR more than 
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does hypothermia alone. Adding a combination of ROS scavengers to 
CP did not further enhance protection against myocardial dysfunction 
during IR, but did provide modest improvement against infarction 
when MCG was added to CP. Mitochondrial dysfunction was reduced 
equivalently with CP treatment with or without the ROS scavengers 
compared to the non-treated, control hearts. However, O2•− emission 
was lower during IR, and FAD remained more reduced during ischemia 
when the CP+MCG group was compared to the CP group. 
Cold CP is widely used for cardiac preservation because it 
reduces the energy demand which helps to rapidly regenerate ATP on 
reperfusion.2 Hypothermia decreases the rate at which intracellular 
enzymes degrade essential cellular components for organ viability 
during ischemia.29 Although hypothermia is the most effective method 
to preserve hearts during ischemic storage, hypothermia itself has 
deleterious effects on contractile element and endothelial cell function 
as the cooling becomes more severe. These defects include cytosolic 
and mCa2+ loading due to impaired ion pumps.1, 25 Moreover, 
hypothermia even without concomitant ischemia increases ROS levels 
likely by increasing ROS generation and/or reducing ROS scavenging,9 
which results in mitochondrial and cellular damage proportional to the 
degree and duration of hypothermia. In a previous study,2 we showed 
that the SOD mimetic, MnTBAP, used alone without CP, did not protect 
against ischemic damage due to increased O2•− downstream products 
like H2O2 and OH•. But when combined with catalase and glutathione 
(MCG), cardiac protection was characterized by better normalization of 
the mitochondrial redox state (NADH and FAD), decreased O2•− levels 
and m[Ca2+] loading during and after ischemia, greater contractile 
function on reperfusion, and reduced infarct size. That study indicated 
clearly that cardioprotection obtained by mild hypothermia alone 
during ischemia can be enhanced by selected ROS scavengers 
administered during the period of cold perfusion before ischemia. 
In clinical settings, hypothermic perfusion is seldom used alone. 
It is most often combined with a variety of CP solutions to achieve 
cardiac arrest during ischemia and to optimize post ischemic 
recovery.30-34 Our rationale for using the ROS scavenger cocktail MCG 
with cold CP perfusion was to reduce ROS emission induced by 
hypothermia as we showed earlier.2 Hence in the present study we 
wished to determine if addition of ROS scavengers to cold CP before 
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ischemia would have an additive effect on cardiac protection, and 
more importantly, if this additive protection is associated with a 
reduction in mitochondrial ROS, m[Ca2+], and/or improved redox 
state. Indeed, our data show there was equivalent cardiac functional 
recovery in the two treatment groups after 60 min of reperfusion and 
this was associated with similar preservation of mitochondrial redox 
state (NADH/FAD). Although adding MCG to CP did not further improve 
cardiac recovery after 2 h cold ischemia more than did CP alone, it 
appeared to decrease infarct size, though not significantly. However, 
the CP+MCG group exhibited reduced O2•− emission during ischemia 
compared to both the control and CP groups, and at 30 min 
reperfusion O2•− emission remained lower in the CP+MCG group than 
in the control group. 
It is unclear how CP alone is effective in decreasing ROS. It is 
possible that electron flow through the ETC is diminished due to less 
ATP demand in CP treated hearts, which could result in less electron 
leak and lower O2•− levels. Another possibility could be simply that 
there is more effective ROS scavenging by the endogenous glutathione 
in the CP group. Glutathione is highly regulated by the cytosolic redox 
state and is rapidly taken up from the cytosol via the decarboxylate 
and 2-oxoglutarate transporters.35-37 In this way it effectively links 
changes in the cellular redox state.36, 37 Indeed, one defense against 
IR-induced ROS accumulation and damage may involve preservation of 
the NAD(P)H pool. The NADH/NAD+ level through the NADH kinase and 
transhydrogenase38, 39-dependent mechanism maintains the 
mitochondrial NAD(P)H pool required to maintain the redox status 
necessary for effective scavenging. Thus an increase in NADH, as was 
observed in the CP group, would correlate with increased NAD(P)H 
dependent redox scavenging by glutathione. 
It is unlikely that CP reduced the ROS level indirectly by 
reducing m[Ca2+] since m[Ca2+] was not different between the CP and 
CON groups during ischemia (data not shown). Although high m[Ca2+] 
during ischemia is believed to be an instigator of IR injury, it seems 
that the most damaging Ca2+ influx occurs on reperfusion.40 All 
together, it appears that addition of MCG to CP, although it decreased 
ROS even more than did CP alone during ischemia and during early 
reperfusion, did not markedly enhance the protection afforded by CP 
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alone, which may indicate that not all the ROS generated during 
ischemia is damaging. 
Results from our previous study2 show that hearts treated with 
MnTBAP alone had a worse outcome compared to hearts treated with 
the combination MCG or control hearts. In the present study, when CP 
was combined only with MnTBAP, functional recovery was improved, 
but this improvement was not significantly different from CP plus the 
scavenging cocktail MCG (Table 2). This could be attributed to the 
finding that CP alone reduced O2•− available for scavenging and 
resulted in decreased downstream products of O2*− associated with 
better cardiac recovery. 
Our results showing that addition of MCG to CP did not 
significantly improve cardiac recovery compared to CP alone are 
inconsistent with several studies3, 41-47 that showed improvement in 
cardiac function when ROS scavengers were included. It seems that 
since the production of ROS by cardiac mitochondria in our model 
during cold ischemia is substantially reduced by CP alone, the added 
benefit of ROS scavengers is small. It is clear that in the absence of CP 
during hypothermic protection, the scavenging cocktail provides good 
protection.2 Although we observed reduced O2•− emission during 
ischemia with MCG (Figure 3), superoxide dismutase and catalase may 
not be as effective during ischemia because ROS scavenging enzymes 
are reported to provide more benefit when O2 is restored to previously 
ischemic tissue due to regeneration of reduced scavenging systems.48 
In summary, our data show that hypothermic CP perfusion 
alone before 2 h cold ischemia preserved mitochondrial redox potential 
(NADH, FAD), lowered ROS during subsequent cold IR, and lowered 
m[Ca2+] during reperfusion. Adding ROS scavengers to the cold CP 
perfusate provided limited added cardiac and mitochondria protection, 
but did decrease O2•− emission during ischemia and early reperfusion. 
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